Debra Brown
Nurse Practitioner · Warsaw, NYNPI 1932107885
Payments from drug & device makers
Across 155 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$673
- Pfizer$315
- AstraZeneca$308
- Astellas Pharma US Inc$212
- GSK$165
- Abbott$148
- plus $858 from 22 others
What the payments were for
- Food & beverage$2,49993%
- Education$1807%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $673 |
| Pfizer | 23 | $315 |
| AstraZeneca | 14 | $308 |
| Astellas Pharma US Inc | 9 | $212 |
| GSK | 9 | $165 |
| Abbott | 7 | $148 |
| Lilly USA, LLC | 6 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $93 |
| Bayer | 5 | $91 |
| Amgen | 4 | $66 |
| Paratek Pharmaceuticals, Inc. | 4 | $64 |
| Mylan Specialty L.p. | 2 | $51 |
| Johnson & Johnson | 3 | $50 |
| AbbVie | 3 | $50 |
| Kowa Pharmaceuticals America, Inc. | 1 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Daiichi Sankyo Inc. | 2 | $29 |
| Novartis | 2 | $27 |
| Merck | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Grifols USA, LLC | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Gilead | 1 | $15 |
| Nevro Corp. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
How this compares
$2,679 in reported general payments places this provider in the 90th percentile of 4,112 nurse practitioner providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 207 | $223,861 |
| EliquisApixaban | 181 | $167,345 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 96 | $90,218 |
| JardianceEmpagliflozin | 88 | $76,796 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $54,994 |
| XareltoRivaroxaban | 53 | $47,488 |
| JanuviaSitagliptin Phosphate | 33 | $34,558 |
| TrulicityDulaglutide | 30 | $33,738 |
| FarxigaDapagliflozin Propanediol | 32 | $31,709 |
| LinzessLinaclotide | 35 | $28,582 |
| RybelsusSemaglutide | 18 | $26,122 |
| TradjentaLinagliptin | 25 | $23,596 |
| MyrbetriqMirabegron | 40 | $19,406 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $19,048 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 103 | $18,944 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $673 | $249,982225 claims |
| PfizerEliquis, Paxlovid | $315 | $172,664195 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $17 | $109,924125 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $165 | $109,042119 claims |
| Johnson & JohnsonXarelto | $50 | $47,48853 claims |
| MerckJanuvia | $20 | $34,55833 claims |
| Lilly USA, LLCTrulicity | $98 | $33,73830 claims |
| AbbVieLinzess, Synthroid | $50 | $33,57890 claims |
| AstraZenecaFarxiga | $308 | $31,70932 claims |
| Astellas Pharma US IncMyrbetriq | $212 | $19,40640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in Warsaw
- Patricia McGoldrickNew York$202K
- Michelle DartSyracuse$95K
- Susan KreppelWilliamsville$67K
- Kerry AhernEast Syracuse$55K
- Valerie StanleyAlbany$55K
- Jodi LogerfoNew York$48K
- Grace WlasowiczRochester$41K
- Melissa LevinElmhurst$34K
- Carla JungquistCanandaigua$28K
- Kelly WilmarthJohnson City$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.